Diamyd Medical AB Adds To Previously Reported Positive Efficacy Results With Diamyd(TM) In Type 1 Diabetes Patients At A European Scientific Diabetes Meeting In Copenhagen

STOCKHOLM, Sweden, Sept. 18 /PRNewswire-FirstCall/ -- Diamyd Medical AB (SWEDEN OMXS: DIAM B; OTC: DMYDY) -- Professor Johnny Ludvigsson, Linkoping University Hospital, Linkoping, Sweden and Principal Investigator for the Diamyd(TM) phase II study in 70 patients with recent onset type 1-diabetes, presented further results from the study at the European Diabetes meeting EASD in Copenhagen.